With two deals focused on its antisense drug technology, Ionis Pharmaceuticals has partnered with Empirico and Aro Biotherapeutics. With Empirico, Ionis gains access to its human genetics platform for novel drug discovery and therapeutic target identification to complement Ionis’ antisense technology. With Aro, Ionis plans to develop ASO-Centyrin combination drug candidates for the targeted drug delivery of ASOs covering a range of indications.